JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Myeloid differentiation primary response 88 expression in central nervous system lymphomas
Abstract
Aims: A prominent adaptor protein that signals from many receptors called myeloid differentiation primary response 88 (MYD88) coded by MYD88 gene was evaluated. Our aim was to record the level of MYD88 expression and its relation with clinicopathological parameters in both primary and secondary Central Nervous System (CNS) Lymphomas.
Methods: MYD88 protein expression was analyzed by two different classification using immunohistochemistry (IHC) in ten patients who were diagnosed in our hospital. The samples that were collected from patients before treatment were evaluated and specified by a hematopathologist. Demographic and clinical information of the patients were obtained from hospital database and files. The primary outcome was the presence and prevalence of MYD88 expression. Secondary outcomes were determined as the evaluation of the relationship between MYD88 expression and disease prognosis.
Results: MYD88 protein expression was examined in 10 in-patients of which 9/10 cases (90%) expressed the protein in wide ranges of intensity and density. Six patients (60%) expressed high-level of MYD88 protein where as one patient did not, and three patients (patient 2,3,9) expressed low quantity of MYD88 protein that deceased after diagnosis. Most CNS lymphoma patients had an ABC-like immunophenotype.
Conclusion: Primary and secondary CNS lymphomas showed expression of MYD 88 protein without regards of lymphoma subtype.

Keywords : Central nervous system lymphoma, immunohistochemistry, MYD88

Download Article


1. Swerdlow SHC E, Harris NL, Jaffe ES et al. WHO classification of tumours of hematopoietic and lymphoid tissues. Revised. 4th ed. 2017.
2. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.<em>Blood</em>. 2004;103(1):275-282.
3. Akira S, Takeda K. Toll-like receptor signalling. <em>Nat Rev Immunol</em>. 2004; 4(7):499-511.
4. Lim KH, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-kappaB in lymphoid malignancies.<em> Immunol Rev</em>. 2012; 246(1):359-378.
5. Fukumura K, Kawazu M, Kojima S, et al. Genomic characterization of primary central nervous system lymphoma.<em> Acta Neuropathol</em>. 2016;131(6): 865-875.
6. Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. <em>Acta Neuropathol.</em> 2011; 122(6):791-792.
7. Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton&rsquo;s tyrosine kinase in B cell malignancies. <em>Nat Rev Cancer</em>. 2014;14(4):219-232.
8. Caner V, Sen Turk N, Baris IC, Cetin GO, Tepeli E, Hacioglu S, et al. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas. <em>Genet Test Mol Biomarkers</em>. 2015;19(7):372-378.
9. Fox CP, Phillips EH, Smith J, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. <em>Br J Haematol.</em> 2019;184(3):348-363.
10. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. <em>Nature</em>. 2009; 459(7247):717-721.
11. Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. <em>Blood.</em> 2006;107(1):190-196.
12. Choi JW, Kim Y, Lee JH, Kim YS. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. <em>Hum Pathol</em>. 2013;44(7):1375-1381.
13. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <em>Nature</em>. 2010;463(7277):88-92.
Article available in :
Volume 2, Issue 4, 2024
Page : 83-86
https://doi.org/10.51271/JCHOR-0045
Article Information
Received : 20 Mar 2024
Accepted : 26 Haz 2024
Published : 14 Kas 2024
Corresponding Author :

Berrin Balık: Department of Hematology, Gazi Yaşargil Training and Research Hospital, Diyarbakır, Turkey

[email protected]
Citation : Balık B, Mutlu YG, Sevindik ÖG. Myeloid differentiation primary response 88 expression in central nervous system lymphomas. J Curr Hematol Oncol Res. 2024;2(4):83-86.

Read: 66
Cited: 0
Download : 45
_Footer